RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Newton ACS Wong, David Gonzalez de Castro, Manuel Salto-Tellez, Rachel Butler, Salvador J Diaz-Cano, Mohammad Ilyas, William Newman, Emily Shaw, Philippe Taniere, Shaun V Walsh, Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.

Original languageEnglish
Pages (from-to)751-757
Number of pages7
JournalJournal of Clinical Pathology
Volume67
Issue number9
Early online date04 Jul 2014
DOIs
Publication statusPublished - 2014

Keywords

  • Carcinoma
  • Colorectal Neoplasms
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm
  • GTP Phosphohydrolases
  • Genetic Predisposition to Disease
  • Genetic Testing
  • Humans
  • Individualized Medicine
  • Membrane Proteins
  • Mutation
  • Phenotype
  • Predictive Value of Tests
  • Prognosis
  • Proto-Oncogene Proteins
  • Quality Control
  • Quality of Health Care
  • Tumor Markers, Biological
  • ras Proteins

Fingerprint Dive into the research topics of 'RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group'. Together they form a unique fingerprint.

Cite this